Navigation Links
Gerresheimer Sells Technical Plastics Business
Date:7/1/2009

DUSSELDORF, Germany, July 1 /PRNewswire-FirstCall/ -- Gerresheimer AG, a leading manu­facturer of glass and plastic products for the pharma & life science industry, has sold its Technical Plastics operations, which are not part of the MDAX company's core business, to the FBH Group, Bad Soden, Germany. "Through the sale of the Technical Plastics segment Gerresheimer has - as formerly announced - taken a further step in its focus on the core business of pharma & life science," says Dr. Axel Herberg, CEO of Gerresheimer AG.

The Technical Plastics business has so far been part of Gerresheimer Wilden GmbH. Complex injection-molded plastic components for the automobile industry are manufactured by around 430 employees at plants in Germany, the Czech Republic and Mexico. Sales by this business, including the tool business which is also being sold, totaled EUR74m in the financial year 2008.

The purchaser is a company in the FBH Group, Bad Soden, to which Thermoplast Technik Beteiligungs-AG, a medium-sized manufacturer of injection-molded parts, belongs. Components for the auto­mobile industry are manufactured in five production plants. Through the sale, FBH will expand its plant network and existing product range.

The purchase price including the debts taken over amounts to EUR12m. The transfer takes place with effect from July 1, 2009.

About Gerresheimer

Gerresheimer employs around 10,000 people in 40 locations in Europe, America and Asia. In the financial year 2008, worldwide sales totaled EUR1.06bn. The product portfolio ranges from pharma­ceu­tical vials made of glass and plastic through to complex drug-delivery systems for the pharma & life science industry. These include sterile syringes, inhalers and other system-based approaches for safe dosage and application of medications. The Group enjoys a leading position in markets which are characterized by
'/>"/>

SOURCE Gerresheimer AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Yves Lionel Assant is New Chairman of Gerresheimers Supervisory Board
2. 2007 Another Record Year in Terms of Sales and Earnings for Gerresheimer
3. Gerresheimer: Record Year in 2007 and Positive Outlook for 2008
4. Moodys Raises Rating for Gerresheimer
5. Gerresheimer Discontinues Marginal Operations
6. Gerresheimer Further Increases its Sales and Earnings Power
7. Gerresheimer Starts Process to Sell off its Business Segment of Technical Plastics
8. Gerresheimer Substantially Increases Quarterly Operating Profit
9. Following a Record Year in 2008 Gerresheimer Again Sets its Sights on Substantial Growth in 2009
10. 2008 a Record Year for Gerresheimer
11. Gerresheimer Opens New High-Tech Production Facility for Pharma Glass in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... -- Research and Markets  has announced the ... report to their offering. ... Metabonomics is the scientific study of chemical processes ... technique that is being widely used in biology, ... molecules that are present in blood, urine, and ...
(Date:7/25/2014)... San Diego, CA (PRWEB) July 25, 2014 ... “Paws” For Your Pet with Lorry Young will be ... DVM, to talk about stem cell therapy in pets. ... discuss the benefits of stem cell therapy for pets suffering ... developments moving the Regenerative Veterinary Medicine industry forward. , Young ...
(Date:7/25/2014)... 2014 Lawrence Livermore scientists Charles Westbrook ... list of " The World's Most Influential Scientific Minds ... 3,000 researchers who were identified by analyzing citation data ... published the highest-impact work (2002-2012 and 2012-2013). The two ... combustion modeling . , "This recognition is a great ...
(Date:7/25/2014)... 2014 /PRNewswire-iReach/ -- Xybion Corporation, the leading provider ... operating in highly regulated industries, announced today that ... User Group Conference, Xybion International Exchange, on October ... at the Sheraton Society Hill Hotel.  ... This year,s conference theme is Compliance ...
Breaking Biology Technology:Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3
... /PRNewswire-Asia-FirstCall/ -- China Sky One Medical,Inc. ("China Sky ... CSKI ), a leading,fully integrated pharmaceutical company producing ... today announced that the Company,s,Chief Financial Officer, Mr. ... at the upcoming Roth 21st Annual OC Growth ...
... COTTAGE, N.Y., Feb. 5 XTL,Biopharmaceuticals Ltd. (Nasdaq: ... February 3, 2009 the Company received a letter from ... outstanding ordinary shares requesting the,convening of an extraordinary shareholders, ... address and approve the following matters: , ...
... Va., Feb. 5, 2009 AMERIGROUP Chairman and Chief ... on legislation expanding the State Children,s Health Insurance Program ... of America,s children deserve a healthy start in life, ... see a family doctor and get the healthcare they ...
Cached Biology Technology:China Sky One Medical, Inc. CFO to Present at Roth Conference 2China Sky One Medical, Inc. CFO to Present at Roth Conference 3Corrected: XTL Biopharmaceuticals to Convene Extraordinary Shareholders' Meetings after Receipt of Shareholder Letter 2AMERIGROUP Praises Expansion of State Children's Health Insurance Program (SCHIP) 2
(Date:7/25/2014)... For the first time, Spanish researchers have detected an ... coli cells are introduced into a droplet of ... the sodium chloride crystallisation to create biomineralogical biosaline 3D ... rehydrating the material, bacteria are revived. The discovery was ... made the cover of the Astrobiology journal ...
(Date:7/24/2014)... Scientists at The New York Stem Cell Foundation ... creating a viable cell replacement therapy for multiple ... For the first time, NYSCF scientists generated induced ... of patients with primary progressive multiple sclerosis and ... these stem cells into becoming oligodendrocytes, the myelin-forming ...
(Date:7/24/2014)... 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced ... control Phase 3 study of Zerenex (ferric citrate), the ... treatment of hyperphosphatemia in patients with end-stage renal disease ... iRon delivery with FErric CiTrate in EsrD) was published ... Society of Nephrology ( JASN ). ...
Breaking Biology News(10 mins):Bacteria manipulate salt to build shelters to hibernate 2NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... for the body to make estrogen, are no longer a ... Ghosh lab at the Hauptman-Woodward Medical Research Institute (HWI) in ... three-dimensional structure of aromatase is the first time that scientists ... In fact, the Ghosh lab has determined the ...
... shows the resistance of the avian flu virus to a ... selection, with researchers documenting the trend in more than 30 ... Influenza A subtype dubbed H5N1, is evolving a resistance to ... two classes of antiviral drugs used to prevent and treat ...
... drug therapy called fenobam has shown promising initial results and ... with Fragile X syndrome (FXS). Findings of the open ... and the University of California, Davis, Medical Center are to ... Journal of Medical Genetics . Results of ...
Cached Biology News:HWI scientist first in world to unravel structure of key breast cancer target enzyme 2HWI scientist first in world to unravel structure of key breast cancer target enzyme 3Avian flu becoming more resistant to antiviral drugs, says University of Colorado study 2Avian flu becoming more resistant to antiviral drugs, says University of Colorado study 3Promising new drug being evaluated as possible treatment option for fragile X syndrome 2
... CL3 series is designed to enhance ... clinical applications at a reasonable cost. ... quick connect rotors and various biocontainment ... interface allows you to control and ...
... tradition of progressive centrifuge design and manufacturing, ... Centra-CL3 and Centra-CL3R (refrigerated) general purpose models ... Quality Control Over Sample Preparation , The ... to 99 protocols and has speed and ...
p230 trans Golgi Purified Anti-Human clone 15, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
... DNA Polymerase I Large (Klenow) Fragment, ... that lacks both the 5´→3´ and the ... coli DNA Polymerase I (1,2). It is ... in strand displacement amplification (5). Klenow Fragment, ...
Biology Products: